About Recombine
Recombine is a company based in New York (United States) founded in 2011 was acquired by CooperSurgical in May 2016.. Recombine has raised $12.07 million across 3 funding rounds from investors including FirstMark, Vast Ventures and Zach Weinberg. Recombine offers products and services including Paragard, Endosee Advance System, and RUMI II. Recombine operates in a competitive market with competitors including Natera, Invitae, Helix, Myriad Genetics and BillionToOne, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Coopersurgical, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$12.07 M (USD)
in 3 rounds
-
Latest Funding Round
$8.44 M (USD), Series B
Jul 06, 2016
-
Investors
FirstMark
& 5 more
-
Employee Count
Employee Count
-
Acquired by
CooperSurgical
(May 25, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Recombine
Recombine offers a comprehensive portfolio of products and services, including Paragard, Endosee Advance System, and RUMI II. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Intrauterine device for long-term birth control.
Device for hysteroscopic visualization and diagnostics.
Surgical manipulator for uterine procedures.
Funding Insights of Recombine
Recombine has successfully raised a total of $12.07M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $8.44 million completed in July 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $8.4M
-
First Round
First Round
(25 Feb 2014)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2016 | Amount | Series B - Recombine | Valuation |
investors |
|
| Oct, 2015 | Amount | Debt – Conventional - Recombine | Valuation |
investors |
|
| Feb, 2014 | Amount | Series A - Recombine | Valuation | FirstMark |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Recombine
Recombine has secured backing from 6 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include FirstMark, Vast Ventures and Zach Weinberg. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US focused venture capital firm
|
Founded Year | Domain | Location | |
|
Early-stage venture capital is invested in tech startups across sectors.
|
Founded Year | Domain | Location | |
|
Offers medical devices for fertility, contraception, and women's health care globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Recombine
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Recombine
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Recombine Comparisons
Competitors of Recombine
Recombine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Natera, Invitae, Helix, Myriad Genetics and BillionToOne, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| domain | founded_year | HQ Location |
Home-based genetic tests for detecting diseases are provided to individuals.
|
|
| domain | founded_year | HQ Location |
Genomic database for clinical research is provided.
|
|
| domain | founded_year | HQ Location |
Molecular diagnostics and personalized medicine for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Provider of cell-free cancer liquid biopsy test
|
|
| domain | founded_year | HQ Location |
Genomic testing services are provided clinically and directly to consumers.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Recombine
Frequently Asked Questions about Recombine
When was Recombine founded?
Recombine was founded in 2011 and raised its 1st funding round 3 years after it was founded.
Where is Recombine located?
Recombine is headquartered in New York, United States. It is registered at New York, New York, United States.
Is Recombine a funded company?
Recombine is a funded company, having raised a total of $12.07M across 3 funding rounds to date. The company's 1st funding round was a Series A of $3.63M, raised on Feb 25, 2014.
What does Recombine do?
Recombine was founded in 2011 in New York, United States, and operates in the genetic testing sector. Clinical services are offered, including CarrierMap for comprehensive carrier screening and ChromoMap for non-invasive prenatal chromosome analysis using maternal blood. Sample collection and genetic counseling are also managed to support testing processes. Operations focus on reducing risks associated with invasive procedures.
Who are the top competitors of Recombine?
Recombine's top competitors include Helix, Natera and Fulgent Genetics.
What products or services does Recombine offer?
Recombine offers Paragard, Endosee Advance System, and RUMI II.
Who are Recombine's investors?
Recombine has 6 investors. Key investors include FirstMark, Vast Ventures, Zach Weinberg, Nat Turner, and Vivek Garipalli.